Details for Patent: 11,142,528
✉ Email this page to a colleague
Which drugs does patent 11,142,528 protect, and when does it expire?
Patent 11,142,528 protects BRUKINSA and is included in one NDA.
This patent has thirty-two patent family members in twenty-six countries.
Summary for Patent: 11,142,528
| Title: | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators |
| Abstract: | The invention is fused heterocyclic compounds of formula (I), and salts thereof, compositions thereof, and methods of use therefor. In particular, disclosed herein are certain fused heterocyclic compounds that can be useful for inhibiting protein kinase, including Bruton's tyrosine kinase (Btk), and for treating disorders mediated thereby. ##STR00001## |
| Inventor(s): | Wang; Zhiwei (Beijing, CN), Guo; Yunhang (Beijing, CN) |
| Assignee: | BEIGENE SWITZERLAND GMBH (Basel, CH) |
| Application Number: | 16/739,447 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; Dosage form; |
Drugs Protected by US Patent 11,142,528
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA | ⤷ Sign Up | |||
| Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) | ⤷ Sign Up | |||
| Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA | ⤷ Sign Up | |||
| Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 11,142,528
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| China | PCT/CN2013/074728 | Apr 25, 2013 |
International Family Members for US Patent 11,142,528
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2989106 | ⤷ Sign Up | 301161 | Netherlands | ⤷ Sign Up |
| European Patent Office | 2989106 | ⤷ Sign Up | PA2022504 | Lithuania | ⤷ Sign Up |
| European Patent Office | 2989106 | ⤷ Sign Up | LUC00250 | Luxembourg | ⤷ Sign Up |
| European Patent Office | 2989106 | ⤷ Sign Up | CA 2022 00008 | Denmark | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
